Why Abbott (ABT) Could Beat Earnings Estimates Again


Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Abbott (ABT), which belongs to the Zacks Medical – Products industry, could be a great candidate to consider.

This maker of infant formula, medical devices and drugs has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 34.01%.

For the last reported quarter, Abbott came out with earnings of $1.40 per share versus the Zacks Consensus Estimate of $0.92 per share, representing a surprise of 52.17%. For the previous quarter, the company was expected to post earnings of $1.01 per share and it actually produced earnings of $1.17 per share, delivering a surprise of 15.84%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Abbott lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Abbott currently has an Earnings ESP of +3.86%, which suggests that analysts have recently become bullish on the company’s earnings prospects. This positive Earnings ESP when combined with the stock’s Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company’s next earnings report to be released on January 26, 2022.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it’s really important to check a company’s Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they’ve reported.

Zacks’ Top Picks to Cash in on Artificial Intelligence

This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.

See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>

Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



Source link

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...